Fundraising Fox
TELA Bio
NASDAQ: TELAMalvern, US · Founded 2012 · 7 known investors
Find your way into TELA Bio
Sign up to see every warm intro you have to TELA Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the TELA Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Offers soft tissue repair solutions combining naturally sourced tissue with polymer; lead product OviTex for hernia repair (NASDAQ: TELA), based in Malvern, PA.
Founders & leadership
TELA Bio was founded in 2012 by Antony Koblish.
AK
Antony KoblishCo Founder2012–2026He has a background in mechanical engineering and product development.
FC
Francis ConwayExecutive
MP
Maarten PersenaireExecutive
CA
Christine ArasinExecutive
Board
KR
AF
Ashley FreidmanBoard director
AO
AF
VB
Vince BurgassBoard director
PT
Paul TouheyBoard director
VB
Vince BurgessBoard director
Investors · 7
Essex Woodlands Healthcare Partnerslisted by Essex Woodlands Healthcare PartnersNew York · $20M – $80M
How we know: Essex Woodlands Healthcare Partners's portfolio page · Not right? Tell us
HighCape Capitallisted by HighCape CapitalWestport
How we know: HighCape Capital's portfolio page · Not right? Tell us
OrbiMedlisted by OrbiMedNew York · $1M – $75M
How we know: OrbiMed's portfolio page · the VCSheet dataset · Not right? Tell us
1315 CapitalinferredPhiladelphia · $5M – $40Mvia Adele C. Oliva · board
How we know: board seat on SEC Form D · Not right? Tell us
RTW Investments L.P.reportedNew York
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$82.7M disclosed across 10 of 11 rounds · 2014–2025
▶$10.6MraisedJul 2019 · 15 investors · BiotechnologyRule 506(b)
▶$10.6MraisedJul 2019 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Antony KoblishExecutive Officer, Director
- Ashley FriedmanDirector
- Matt ZugaDirector
- Kurt AzarbarzinDirector
- Nora BrennanExecutive Officer
- Adele OlivaDirector
- Maarten PersenaireExecutive Officer
- Francis ConwayExecutive Officer
- Ronald J. Ellis, Jr.Director
- Vince BurgessDirector
- Offering amount
- $20M
- Amount sold
- $10.6M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedDec 2018 · 8 investors · BiotechnologyRule 506(b)
▶$2.1MraisedDec 2018 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adele OlivaDirector
- Francis ConwayExecutive Officer
- Kevin RakinDirector
- Ronald J. Ellis, Jr.Director
- Antony KoblishExecutive Officer, Director
- Maarten PersenaireExecutive Officer
- Kurt ArarbarzinDirector
- Ashley FriedmanDirector
- Vince BurgessDirector
- Offering amount
- $3.5M
- Amount sold
- $2.1M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$501.1KraisedMay 2018 · 1 investors · BiotechnologyRule 506(b)
▶$501.1KraisedMay 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adele OlivaDirector
- Maarten PersenaireExecutive Officer
- Antony KoblishExecutive Officer, Director
- Kevin RakinDirector
- Francis ConwayExecutive Officer
- Ronald J. Ellis Jr.Director
- Ashley FriedmanDirector
- Vince BurgessDirector
- Christopher SmithExecutive Officer
- Paul TouheyDirector
- Offering amount
- $2M
- Amount sold
- $501.1K
- Minimum investment
- $250K
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$240KraisedMay 2018 · 1 investors · BiotechnologyRule 506(b)
▶$240KraisedMay 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Antony KoblishExecutive Officer, Director
- Ronald J. Ellis, Jr.Director
- Paul TouheyDirector
- Ashley FriedmanDirector
- Maarten PersenaireExecutive Officer
- Francis ConwayExecutive Officer
- Vince BurgessDirector
- Christoper SmithExecutive Officer
- Adele OlivaDirector
- Kevin RakinDirector
- Offering amount
- $240K
- Amount sold
- $240K
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedApr 2018 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedApr 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Antony KoblishExecutive Officer, Director
- Ronald J. Ellis, Jr.Director
- Paul TouheyDirector
- Adele OlivaDirector
- Ashley FriedmanDirector
- Christopher SmithExecutive Officer
- Kevin RakinDirector
- Maarten PersenaireExecutive Officer
- Vince BurgessDirector
- Francis ConwayExecutive Officer
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedApr 2018 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedApr 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Maarten PersenaireExecutive Officer
- Christopher SmithExecutive Officer
- Ashley FriedmanDirector
- Ronald J. Ellis, Jr.Director
- Francis ConwayExecutive Officer
- Kevin RakinDirector
- Paul TouheyDirector
- Adele OlivaDirector
- Antony KoblishExecutive Officer, Director
- Vince BurgessDirector
- Offering amount
- $1M
- Amount sold
- $500K
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15MraisedNov 2017 · 1 investors · BiotechnologyRule 506(b)
▶$15MraisedNov 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Antony KoblishExecutive Officer, Director
- Kevin RakinDirector
- Christopher SmithExecutive Officer
- Paul TouheyDirector
- Francis ConwayExecutive Officer
- Adele OlivaDirector
- Maarten PersenaireExecutive Officer
- Vince BurgessDirector
- Ashley FriedmanDirector
- Offering amount
- $25M
- Amount sold
- $15M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.4MraisedJan 2017 · 16 investors · BiotechnologyRule 506(b)
▶$7.4MraisedJan 2017 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vince BurgassDirector
- Kevin RakinDirector
- Ashley FreidmanDirector
- Francis ConwayExecutive Officer
- Maarten PersenaireExecutive Officer
- Antony KoblishExecutive Officer, Director
- Paul TouheyDirector
- Adele OlivaDirector
- Offering amount
- $7.5M
- Amount sold
- $7.4M
- Minimum investment
- $50K
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$230.5Mvaluation at IPOJun 2020 · $16.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Founder mafia
4 people who came through TELA Bio went on to found or lead other companies.
Frequently asked questions
- What does TELA Bio do?
- Offers soft tissue repair solutions combining naturally sourced tissue with polymer; lead product OviTex for hernia repair (NASDAQ: TELA), based in Malvern, PA.
- Who founded TELA Bio?
- TELA Bio was founded by Antony Koblish in 2012.
- Who are TELA Bio's investors?
- TELA Bio's investors include Checkmate Capital Group LLC, Essex Woodlands Healthcare Partners, HighCape Capital, OrbiMed, Signet Healthcare Partners, 1315 Capital, RTW Investments L.P..
- How much funding has TELA Bio raised?
- TELA Bio has disclosed $82.7M raised across 10 of its 11 known rounds.
- Where is TELA Bio headquartered?
- TELA Bio is headquartered in Malvern, US.